Sandoz Moves Ahead With High-Concentration Adalimumab In Europe

Approval For Humira Rival’s 100mg/ml Formulation Follows FDA Nod Last Month

Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.

Europe from space sunrise new dawn
Sandoz has a European approval for high-concentration adalimumab • Source: Deco / Alamy Stock Photo

More from Biosimilars

More from Products